Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins, Sofiya Latifyan, Gerasimos P. Sykiotis et al. · Nature Reviews Clinical Oncology · 2019
Cited by 2,294 works. doi:10.1038/s41571-019-0218-0 Open-access PDF
Authors
- Filipe Martins
- Sofiya Latifyan
- Gerasimos P. Sykiotis
- Faïza Lamine
- Michel H. Maillard
- Montserrat Christinet Fraga
- Keyvan Shabafrouz
- Camillo Ribi
- Anne Cairoli
- Yan Guex‐Crosier
- Thierry Küntzer
- Olivier Alain Michielin
- Solange Peters
- George Coukos
- François Spertini
- John A. Thompson
- Michel Obéid
References
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- The National Comprehensive Cancer Network
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Pembrolizumab versus Ipilimumab in Advanced Melanoma